The United States market has shown robust performance, climbing 1.5% in the last week and an impressive 26% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying undervalued stocks like ARKO Petroleum and others can offer potential opportunities for investors seeking value amidst rising market trends.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
Name
Current Price
Fair Value (Est)
Discount (Est)
Tuniu (TOUR)
$5.94
$11.44
48.1%
Travere Therapeutics (TVTX)
$42.84
$84.03
49%
Rayonier (RYN)
$20.34
$39.91
49%
Ramaco Resources (METC)
$16.51
$32.27
48.8%
Kaspi.kz (KSPI)
$86.38
$171.76
49.7%
iRhythm Holdings (IRTC)
$118.31
$234.30
49.5%
FinWise Bancorp (FINW)
$12.98
$25.54
49.2%
FB Financial (FBK)
$52.04
$101.61
48.8%
CVR Energy (CVI)
$34.39
$67.81
49.3%
Bitgo Holdings (BTGO)
$11.89
$23.26
48.9%
Let’s dive into some prime choices out of the screener.
Overview: ARKO Petroleum Corp. operates as a fuel distributor in North America with a market cap of $955.69 million.
Operations: The company’s revenue segments include fuel distribution as its primary business operation in North America.
Estimated Discount To Fair Value: 30.4%
ARKO Petroleum is trading at US$21.55, significantly undervalued compared to its estimated future cash flow value of US$30.95. Despite revenue growth forecasted at 4.4% annually—slower than the market average—earnings are expected to grow significantly by 23.6% per year, outpacing the broader U.S. market’s growth rate of 16.7%. Recent earnings showed improved net income and EPS, indicating potential for robust cash flow generation despite challenges in covering interest payments with earnings alone.
APC Discounted Cash Flow as at May 2026
Overview: MannKind Corporation is a biopharmaceutical company that specializes in developing solutions for chronic disease care, with a market cap of approximately $1.04 billion.
Operations: The company’s revenue is primarily derived from its pharmaceuticals segment, totaling $360.78 million.
Estimated Discount To Fair Value: 30.5%
MannKind, trading at US$3.28, is undervalued with an estimated future cash flow value of US$4.72. Despite recent volatility and a net loss of US$16.62 million in Q1 2026, its forecasted annual earnings growth rate exceeds market averages as it aims for profitability within three years. Revenue growth is slower at 11.8% annually but remains above the U.S. market average, supporting MannKind’s potential for long-term cash flow improvement amidst industry challenges.
